16 October 2018
LNC Therapeutics acquires exclusive license for the Christensenella patent from Cornell University
LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders
Life Sciences
4 October 2018
Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human...
1 October 2018
LNC Therapeutics launches a new clinical trial, OBEMINALE 2, and treats its first patient
LNC Therapeutics, a French biotech company specialized in the gut microbiome-based drug discovery,has announced the launch of a new clinical trial with Stablor®, OBEMINALE 2,...
30 April 2018
Seventure Partners invests in A-Mansia
A-Mansia Biotech S.A., a belgian microbiome company, announces a €13 million first close of its Series A financing, led by Seventure Partners.
21 March 2018
Adisseo and Seventure Partners announce €24m First Close of AVF, a New Fund Dedicated to Innovative Animal Health and Nutrition
Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in Life science microbiome investment, today announces that it has launched AVF, the...
8 March 2018
MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation
MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial in...
4 January 2018
Zipongo extends total financing to over $50M to launch FoodScripts™ and lower chronic disease costs
Zipongo plans to use the additional funding to expand its nutrition platform beyond wellness to use food as first-line therapy in treating chronic disease.
7 December 2017
Vedanta Biosciences announces initiation of Phase 1a/1b trial for new drug class of rationally-defined bacteria consortia derived from the human microbiome
VE303 is first known rationally-defined bacterial consortium in powder form to enter the clinic and has recieved Orphan Drug designation from the US FDA for C. difficile...
1 December 2017
Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy
New collaborations with Leiden University Medical Center and the Mitchell Cancer Institute focused on melanoma and cancers of the bladder, head and neck, and kidneys
13 November 2017
Enhanced understanding of the microbiome is helping medicine via The Economist
Enterome, Eligo Bioscience and Seventure Partners inside !